Skip to main content
Top
Published in: Diagnostic Pathology 1/2019

Open Access 01-12-2019 | Urothelial Cancer | Research

Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?

Published in: Diagnostic Pathology | Issue 1/2019

Login to get access

Abstract

Background

Urothelial carcinoma in situ (CIS) in the bladder can be difficult to diagnose due to factors including procedural artifact, minimal tissue sampled, therapy-related changes, and various CIS growth patterns. Prior data has demonstrated an increase in alpha-methylacyl-CoA-racemase (AMACR) in urothelial CIS, but there is no information on its utility for diagnosing difficult cases. The aim of this investigation was to assess the expression of AMACR that was ordered on equivocal bladder cases during clinical practice.

Methods

Transurethral resections of the bladder in which AMACR and CK20 were performed during diagnostic workup were identified and cases with a final diagnosis of CIS (n = 22) or non-neoplastic urothelium (n = 30) were selected. Additionally, cases in which a diagnosis of CIS was rendered without IHC (n = 20) were selected and tested for AMACR expression.

Results

Sensitivity of AMACR for CIS diagnosed with IHC during clinical practice was 73% and specificity was 97%, while CK20 was 95% sensitive and 80% specific. Sensitivity of AMACR in CIS diagnosed without IHC was 100%. In all groups, AMACR had inconsistent intensity, compared to CK20 which had consistent, strong intensity.

Conclusions

AMACR was usually positive in urothelial CIS and negative in non-neoplastic urothelium. However, it is important to note that AMACR was less sensitive in difficult cases, while CK20 was more sensitive with more consistent, strong staining compared to AMACR.
Literature
1.
go back to reference Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010;184(1):74–80.PubMedPubMedCentralCrossRef Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010;184(1):74–80.PubMedPubMedCentralCrossRef
2.
go back to reference Van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493–500.PubMedCrossRef Van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493–500.PubMedCrossRef
3.
go back to reference Zieger K, Jensen KM. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome. Scand J Urol Nephrol. 2011;45(6):411–8.PubMedCrossRef Zieger K, Jensen KM. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome. Scand J Urol Nephrol. 2011;45(6):411–8.PubMedCrossRef
4.
go back to reference Nese N, Gupta R, Bui MH, Amin MB. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Cancer Netw. 2009;7(1):48–57.CrossRef Nese N, Gupta R, Bui MH, Amin MB. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis. J Natl Compr Cancer Netw. 2009;7(1):48–57.CrossRef
5.
go back to reference Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000;163(4):1124–9.PubMedCrossRef Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000;163(4):1124–9.PubMedCrossRef
6.
go back to reference Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S, Witjes JA, Black PC. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67(5):876–88.PubMedCrossRef Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, Shariat S, Witjes JA, Black PC. Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol. 2015;67(5):876–88.PubMedCrossRef
7.
go back to reference Asgari M, Nabi Maybodi M, Abolhasani M. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran. 2016;30:400.PubMedPubMedCentral Asgari M, Nabi Maybodi M, Abolhasani M. Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: analysis of CK20, CD44, P53 and Ki67. Med J Islam Repub Iran. 2016;30:400.PubMedPubMedCentral
8.
go back to reference Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W, Brimo F. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Ann Diagn Pathol. 2014;18(1):27–32.PubMedCrossRef Jung S, Wu C, Eslami Z, Tanguay S, Aprikian A, Kassouf W, Brimo F. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Ann Diagn Pathol. 2014;18(1):27–32.PubMedCrossRef
9.
go back to reference Edgecombe A, Nguyen BN, Djordjevic B, Belanger EC, Mai KT. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Appl Immunohistochem Mol Morphol. 2012;20(3):264–71.PubMedCrossRef Edgecombe A, Nguyen BN, Djordjevic B, Belanger EC, Mai KT. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia. Appl Immunohistochem Mol Morphol. 2012;20(3):264–71.PubMedCrossRef
10.
go back to reference Yin H, He Q, Li T, Leong AS. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol. 2006;14(3):260–5.PubMedCrossRef Yin H, He Q, Li T, Leong AS. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium. Appl Immunohistochem Mol Morphol. 2006;14(3):260–5.PubMedCrossRef
11.
go back to reference Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005;55(5):248–54.PubMedCrossRef Kunju LP, Lee CT, Montie J, Shah RB. Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia. Pathol Int. 2005;55(5):248–54.PubMedCrossRef
12.
go back to reference Mallofré C, Castillo M, Morente V, Solé M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16(3):187–91.PubMedCrossRef Mallofré C, Castillo M, Morente V, Solé M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16(3):187–91.PubMedCrossRef
13.
go back to reference McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.PubMedCrossRef McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25(8):1074–8.PubMedCrossRef
14.
go back to reference Arias-Stella JA 3rd, Shah AB, Gupta NS, Williamson SR. CK20 and p53 Immunohistochemical staining patterns in urinary bladder specimens with equivocal atypia. Arch Pathol Lab Med 2018;142(1):64–69.CrossRef Arias-Stella JA 3rd, Shah AB, Gupta NS, Williamson SR. CK20 and p53 Immunohistochemical staining patterns in urinary bladder specimens with equivocal atypia. Arch Pathol Lab Med 2018;142(1):64–69.CrossRef
15.
go back to reference Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26(7):926–31.PubMedCrossRef Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol. 2002;26(7):926–31.PubMedCrossRef
16.
go back to reference Gunia S, May M, Scholmann K, Störkel S, Hoschke B, Koch S, Dietel M, Kristiansen G. Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer. Virchows Arch. 2008;453(2):165–70.PubMedCrossRef Gunia S, May M, Scholmann K, Störkel S, Hoschke B, Koch S, Dietel M, Kristiansen G. Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer. Virchows Arch. 2008;453(2):165–70.PubMedCrossRef
17.
go back to reference Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol. 2003;34(8):792–6.PubMedCrossRef Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol. 2003;34(8):792–6.PubMedCrossRef
18.
go back to reference Langner C, Rupar G, Leibl S, Hutterer G, Chromecki T, Hoefler G, Rehak P, Zigeuner R. Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 2005;448(3):325–30.PubMedCrossRef Langner C, Rupar G, Leibl S, Hutterer G, Chromecki T, Hoefler G, Rehak P, Zigeuner R. Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 2005;448(3):325–30.PubMedCrossRef
19.
go back to reference Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol. 2013;37(12):1815–23.PubMedCrossRef Aron M, Luthringer DJ, McKenney JK, Hansel DE, Westfall DE, Parakh R, Mohanty SK, Balzer B, Amin MB. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol. 2013;37(12):1815–23.PubMedCrossRef
20.
go back to reference Fellegara G, Gabba S, Dorji T, De Luca G, Colecchia M. Observations on Aron et al's "utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia". Am J Surg Pathol. 2014;38(7):1013–5.PubMedCrossRef Fellegara G, Gabba S, Dorji T, De Luca G, Colecchia M. Observations on Aron et al's "utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia". Am J Surg Pathol. 2014;38(7):1013–5.PubMedCrossRef
Metadata
Title
Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Publication date
01-12-2019
Published in
Diagnostic Pathology / Issue 1/2019
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0871-8

Other articles of this Issue 1/2019

Diagnostic Pathology 1/2019 Go to the issue